SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-060473
Filing Date
2022-05-13
Accepted
2022-05-13 17:16:29
Documents
13
Period of Report
2022-05-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2215560d1_8k.htm   iXBRL 8-K 25289
2 EXHIBIT 99.1 tm2215560d1_ex99-1.htm EX-99.1 12926
  Complete submission text file 0001104659-22-060473.txt   217064

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scps-20220511.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scps-20220511_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scps-20220511_pre.xml EX-101.PRE 22609
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2215560d1_8k_htm.xml XML 3705
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39788 | Film No.: 22924017
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences